Related Experiment Video
Updated: Jul 18, 2026

05:56
Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
Published on: April 3, 2016
ReCell Combined With NB-UVB for the Treatment of Extensive Stable Vitiligo: A Randomized Controlled Trial
Xueya Tong1, Zhiming Yuan1, Yu Lei2
1Chengdu Borun Vitiligo Hospital, Dermatology, Chengdu, China.
Journal of Cosmetic Dermatology
|February 12, 2025
Abstract
No abstract available in PubMed .
Related Concept Videos
Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Blinding
3.8K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
3.8K

